stars 1 stars 2 stars 3

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated in two confirmatory global studies for the treatment of Huntington’s disease (PRECISE-HD study) and for ALS (PREVAiLS study). The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.

Prilenia Questions

The Prilenia annual revenue was $186000 in 2026.

Limor Har is the Chief Operating Officer (COO) of Prilenia.

39 people are employed at Prilenia.

The NAICS codes for Prilenia are [54, 541, 5417, 54171, 541714].

The SIC codes for Prilenia are [873, 87].

Top Prilenia Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users